Richard A. Miller

Richard A. Miller, M.D is a clinical oncologist and biotech entrepreneur with over 25 years of experience developing new treatments for cancer. He is currently the President and CEO of Pharmacyclics, a California-based biotechnology company specializing in drug development and research in oncology, which he co-founded in April 1991. Before Pharmacyclics, he was Vice President and Director at IDEC Pharmaceuticals Corporation, another public biotechnology company he co-founded in 1984. At IDEC, he pioneered the development of rituximab, now widely used for the treatment of most lymphomas and several autoimmune diseases such as rheumatoid arthritis, and notably the second most commonly used cancer treatment overall.

Dr. Miller is also a Clinical Professor of Medicine (Oncology) at Stanford University Medical Center. He has been published in The Wall Street Journal, Scientific American online, and keeps his own blog at www.yourcanceryourchoice.com/blog. He has authored or co-authored over 100 peer review articles in scientific journals and is a frequently invited speaker at scientific and business conferences. He received his M.D., summa cum laude, from the State University of New York Medical School and is board certified in both Internal Medicine and Medical Oncology.